CASP3 and neoplasm: Figures 6b and c show that cotreatment with SAHA and vemurafenib inhibited tumor growth to similar extents in xenografts deficient in caspase-3 and those carrying control shRNA, although caspase-3 was activated in the latter as shown by the analysis of xenograft samples harvested during treatment (Figure 6d).